Unknown

Dataset Information

0

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.


ABSTRACT: BACKGROUND:Pyrazinamide still may be a useful drug for treatment of rifampin-resistant (RR-TB) or multidrug-resistant tuberculosis (MDR-TB) in China while awaiting scale up of new drugs and regimens including bedaquiline and linezolid. The level of pyrazinamide resistance among MDR-TB patients in China is not well established. Therefore, we assessed pyrazinamide resistance in a representative sample and explored determinants and patterns of pncA mutations. METHODS:MDR-TB isolates from the 2007 national drug resistance survey of China were sub-cultured and examined for pyrazinamide susceptibility by BACTEC MGIT 960 method. pncA mutations were identified by sequencing. Characteristics associated with pyrazinamide resistance were analyzed using univariable and multivariable log-binominal regression. RESULTS:Of 401 MDR-TB isolates, 324 were successfully sub-cultured and underwent drug susceptibility testing. Pyrazinamide resistance was prevalent in 40.7% of samples, similarly among new and previously treated MDR-TB patients. Pyrazinamide resistance in MDR-TB patients was associated with lower age (adjusted OR 0.54; 95% CI, 0.34-0.87 for those aged ?60?years compared to

SUBMITTER: Xia H 

PROVIDER: S-EPMC6947908 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.

Xia Hui H   van den Hof Susan S   Cobelens Frank F   Zhou Yang Y   Zhao Bing B   Wang Shengfen S   Zhao Yanlin Y  

BMC infectious diseases 20200107 1


<h4>Background</h4>Pyrazinamide still may be a useful drug for treatment of rifampin-resistant (RR-TB) or multidrug-resistant tuberculosis (MDR-TB) in China while awaiting scale up of new drugs and regimens including bedaquiline and linezolid. The level of pyrazinamide resistance among MDR-TB patients in China is not well established. Therefore, we assessed pyrazinamide resistance in a representative sample and explored determinants and patterns of pncA mutations.<h4>Methods</h4>MDR-TB isolates  ...[more]

Similar Datasets

| S-EPMC9440668 | biostudies-literature
| S-EPMC4325781 | biostudies-literature
| S-EPMC10956945 | biostudies-literature
| S-EPMC4576106 | biostudies-literature
| S-EPMC6986415 | biostudies-literature
| S-EPMC163747 | biostudies-other
| S-EPMC4023728 | biostudies-literature
| S-EPMC6531379 | biostudies-literature
| S-EPMC154692 | biostudies-literature
| S-EPMC2826000 | biostudies-literature